GLP-1 Sales Surge
Sales of diabetes and weight-loss GLP-1 products jumped 25.5% year-over-year to $2.3 billion in the quarter, a key driver of U.S. Healthcare Solutions growth.
At the archive date, Cencora, Inc. was expected to release its Q3 2026 10-Q filing on November 3, 2026, after market close. Last quarter: Cencora's Q3 FY2026 results highlighted robust topline and bottom-line growth driven by the OneOncology acquisition and GLP-1 sales, yet rising costs and debt warrant attention.
EPS Estimate
$4.60
Revenue Estimate
$89.09B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the COR page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Sales of diabetes and weight-loss GLP-1 products jumped 25.5% year-over-year to $2.3 billion in the quarter, a key driver of U.S. Healthcare Solutions growth.
The February 2026 acquisition of OneOncology significantly increased gross profit and operating income, but also drove a 27.5% rise in distribution, selling, and administrative expenses.
Dismissal of opioid litigation led to a $102 million reduction in opioid liability, resulting in a net credit in litigation and opioid-related expenses for the quarter.
Revenue
$84.75B
+5.07% YoY
EPS (Diluted)
$3.94
+11.93% YoY
Gross Margin
4.3%
+0.7 pts YoY
Operating Income
$1.12B
+29.11% YoY
Add COR to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.